TABLE 1.
Overview of SIV vaccine challenge studies
| Study | Vaccine
|
No. of macaques | Timing (wk)
|
Total study duration (wk) | ||
|---|---|---|---|---|---|---|
| Priming | Booster | Immunizations | Challenged | |||
| Aa | Control rAAV2 | Control rAAV2 | 5 | 0, 24 | 38 | 63 |
| rAAV2/SIV | rAAV2/SIV | 5 | ||||
| Bb | Control rAAV2 | Control rAAV2 | 8 | 0, 12 | 15 | 68 |
| rAAV2/SIV | rAAV2/SIV | 8 | ||||
| Cc | Control DNA | Control DNA | 4 | DNA prime (control or SIV) given at weeks 0, 5, and 14; | 28 | 81 |
| Control rAAV2 | 4 | |||||
| SIV DNA | SIV DNA | 4 | DNA or rAAV boost per dose (control or SIV given at 24 weeks) | |||
| rAAV2/SIV | 4 | |||||
a
rAAV2/SIV vaccine contained a mixture of two rAAV particles, gag-PR-ΔRT and rev-gp160.
b
rAAV2/SIV vaccine contained a mixture of three rAAV particles, gag-PR-ΔRT, RT-IN, and rev-gp160.
c
SIV DNA vaccine was a mixture of three plasmids containing the same genes listed in footnote b.
d
Challenge virus was SIVsm/E600 given intravenously. The dose in study A was 2 MID50. In studies B and C, the dose was 50 MID50.